Drug companies Teva Pharmaceutical, Endo Pharmaceuticals and Teikoku Pharma have signed four settlement agreements with the State of California to resolve allegations regarding pay-for-delay deals to prevent cheaper, generic medicines from entering the ma
Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department a